Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis.
Hyperhomocysteinemia exists among patients both in end-stage renal disease and on dialysis and may represent an additional risk factor for increased cardiovascular disease. Supplementation with folic acid may reduce, but not correct, hyperhomocysteinemia. Evidence that lowering blood homocysteine will lessen cardiovascular risk is being sought.
D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology* / Q000209:etiology; D005492:Folic Acid / Q000494:pharmacology; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors
D006710:Homocysteine; D005492:Folic Acid